Trial Profile
MEASuRE: Metreleptin Effectiveness And Safety Registry
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2022
Price :
$35
*
At a glance
- Drugs Metreleptin (Primary)
- Indications Lipodystrophy
- Focus Adverse reactions
- Acronyms MEASuRE
- Sponsors AstraZeneca
- 07 Aug 2020 Planned End Date changed from 1 Oct 2029 to 31 Oct 2031.
- 07 Aug 2020 Planned primary completion date changed from 1 Oct 2029 to 31 Oct 2031.
- 07 Aug 2020 Status changed from not yet recruiting to recruiting.